1617 JFK Blvd., Suite 500
Philadelphia, PA 19103
Phone: (215) 988-0080
Fax: (215) 988-1739
Hemispherx Biopharma, Inc. (or “the Company”) is a specialty pharmaceutical company addressing critical unmet medical needs. The Company has invested over two decades of R&D into safe, effective ways to modulate and amplify the immune system, and is now poised to enter a confirmatory Phase III U.S. trial with an RNA macromolecule that could become the only FDA-approved therapy for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). This candidate, Ampligen®, was approved for CFS/ME in Argentina in August 2016 and is available to patients in Europe through an early access program (EAP). CFS/ME is a debilitating disease with no known treatment to date but very active patient advocacy groups. Hemispherx also holds rights to an FDA-approved product for genital warts, Alferon N Injection®, which is believed to be the world’s only approved natural interferon (IFN). Hemispherx has refined Alferon’s manufacturing to drastically increase efficiencies and reduce costs, and now seeks FDA approval for the new production method before relaunching Alferon. Hemispherx is headquartered in Philadelphia with GMP manufacturing and research facilities in New Jersey.
* The Corporate Snapshot was last updated on November 27, 2016.